Taysha Gene Therapies, Inc. has grown revenue 57% a year over three years and 57% a year over five. Revenue growth, 3-year annual rate: +57% (Biotechnology median +17%). Revenue growth, 5-year rate: +57%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2020 to FY2025, as filed.

TSHATaysha Gene Therapies, Inc.

Healthcare

$4.49+59% 1Y

$4.49

$2.8752 weeks$6.98

Is it growing?

Watch

Revenue shrinking (−32% year on year). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 to watch, 2 without data

Revenue trend−32% in a yearSEC EDGAR · Jun 30, 2026

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TSHA growing?

Taysha Gene Therapies, Inc. has grown revenue 57% a year over three years and 57% a year over five.

+57%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +57%
Revenue growth, 5-year rate · +57% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›